BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Innovations | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Seizures Fruit fly studies suggest inhibiting FAK, integrin β, TLN1, TNS1 or MMP1 could help treat seizures. In a Drosophila model of mechanically induced seizures, an astrocyte-specific RNAi screen identified four genes encoding components...
BC Innovations | Aug 8, 2018
Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4 + T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that...
BC Innovations | Jun 5, 2018
Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Hypertriglyceridemia Rat studies suggest combined inhibition of MMP1 and MMP3 could help treat hypertriglyceridemia. In a rat model of diet-induced hypertriglyceridemia, subcutaneous administration of a previously reported dual MMP1/MMP3 inhibitor decreased liver weight, serum...
BC Innovations | Mar 22, 2018
Translation in Brief

Switching scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients...
BioCentury | Dec 5, 2011
Product Development

Change-up for BATTER-UP

A year after starting a biomarker study in rheumatoid arthritis, a broad-based consortium has been forced to retool its recruitment strategy. The Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis -Unresponsive Populations Consortium had hoped...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Infectious disease Tuberculosis (TB) Matrix metalloproteinase 1 (MMP1) A study in patient tissue and in mice suggests inhibiting MMP1 may be useful as an adjunct therapy to decrease TB-associated lung tissue...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
BioCentury | Dec 20, 2010
Regulation

Label: No; Access: Yes

FDA 's proposal to remove first-line metastatic breast cancer from the label for Avastin bevacizumab and a contradictory decision in Europe are causing concern and confusion among patients anxious about losing access to the drug...
BC Innovations | Jul 30, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; metastases Matrix metalloproteinase 1 (MMP1); ADAM metallopeptidase with thrombospondin type 1 motif 1 (ADAMTS1); epidermal growth factor receptor (EGFR) Studies in mice and...
Items per page:
1 - 10 of 14